Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model
- PMID: 22745334
- DOI: 10.1124/dmd.112.045872
Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model
Abstract
Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (F(I)) and, in turn, the systemic availability (F(sys)) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (Q(Gut)) model stipulate that 1.0, ∼0.05 to 0.3, and ≤0.484× of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (f(Q)), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the Q(Gut) model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < Q(Gut) model < TM in the description of F(I), and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to first-pass removal was the opposite: SFM > Q(Gut) model > TM. The findings suggest that the f(Q) value strongly influences the rate of intestinal metabolism (F(I) and F(sys)) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the f(Q) value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.
Similar articles
-
Theoretical consideration of the properties of intestinal flow models on route-dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM).Biopharm Drug Dispos. 2019 May;40(5-6):195-213. doi: 10.1002/bdd.2184. Biopharm Drug Dispos. 2019. PMID: 31099032
-
Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.Biopharm Drug Dispos. 2017 Apr;38(3):231-250. doi: 10.1002/bdd.2056. Epub 2017 Mar 28. Biopharm Drug Dispos. 2017. PMID: 27977852
-
PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.Curr Drug Metab. 2010 Nov;11(9):743-61. doi: 10.2174/138920010794328931. Curr Drug Metab. 2010. PMID: 21189137 Review.
-
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.Curr Drug Metab. 2010 Nov;11(9):716-29. doi: 10.2174/138920010794328913. Curr Drug Metab. 2010. PMID: 21189140
-
Why we need proper PBPK models to examine intestine and liver oral drug absorption.Curr Drug Metab. 2013 Jan;14(1):57-79. Curr Drug Metab. 2013. PMID: 22935069 Review.
Cited by
-
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.Clin Pharmacokinet. 2016 Jun;55(6):673-96. doi: 10.1007/s40262-015-0351-6. Clin Pharmacokinet. 2016. PMID: 26895020 Free PMC article. Review.
-
The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.Pharmaceutics. 2020 Apr 1;12(4):312. doi: 10.3390/pharmaceutics12040312. Pharmaceutics. 2020. PMID: 32244748 Free PMC article. Review.
-
A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Biopharm Drug Dispos. 2017 Apr;38(3):163-186. doi: 10.1002/bdd.2068. Biopharm Drug Dispos. 2017. PMID: 28152562 Free PMC article.
-
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Clin Pharmacol Ther. 2013. PMID: 23588311 Free PMC article. Review.
-
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Clin Pharmacokinet. 2016 Mar;55(3):369-80. doi: 10.1007/s40262-015-0322-y. Clin Pharmacokinet. 2016. PMID: 26385839
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical